Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

NCT03547271 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1660

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Infections

Interventions

BIOLOGICAL: MenACYW conjugate vaccine
BIOLOGICAL: Meningococcal group A, C, W-135, and Y conjugate vaccine
BIOLOGICAL: DTaP-IPV-HB-Hib vaccine
BIOLOGICAL: Pneumococcal vaccine (13-valent)
BIOLOGICAL: Pneumococcal vaccine (10-valent)
BIOLOGICAL: MMR vaccine

Sponsor

Sanofi Pasteur, a Sanofi Company